Mayank Mamtani
Stock Analyst at B. Riley Securities
(4.45)
# 351
Out of 4,734 analysts
118
Total ratings
43.27%
Success rate
36.52%
Average return
Main Sectors:
Stocks Rated by Mayank Mamtani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTR Nektar Therapeutics | Initiates: Buy | $4 | $0.89 | +348.43% | 1 | Jan 8, 2025 | |
| CGTX Cognition Therapeutics | Upgrades: Buy | $1 → $1.5 | $0.68 | +120.01% | 3 | Dec 19, 2024 | |
| VKTX Viking Therapeutics | Initiates: Buy | $109 | $32.65 | +233.84% | 1 | Nov 22, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Neutral | $194 → $236 | $293.64 | -19.63% | 11 | Nov 5, 2024 | |
| NVAX Novavax | Reiterates: Buy | $23 → $26 | $8.40 | +209.52% | 19 | Oct 10, 2024 | |
| TRVI Trevi Therapeutics | Reiterates: Buy | $6 | $3.76 | +59.57% | 2 | Oct 7, 2024 | |
| CNTA Centessa Pharmaceuticals | Initiates: Buy | $33 | $15.16 | +117.68% | 1 | Sep 19, 2024 | |
| HROW Harrow | Reiterates: Buy | $50 | $33.85 | +47.71% | 1 | Aug 29, 2024 | |
| ALT Altimmune | Reiterates: Buy | $20 | $6.86 | +191.55% | 9 | Aug 12, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Buy | $55 | $19.56 | +181.19% | 6 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $34 | $29.55 | +15.06% | 13 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $5 | $3.00 | +66.67% | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $122 → $92 | $45.74 | +101.14% | 3 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2 | $0.74 | +170.27% | 5 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $3.18 | +25.79% | 3 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $4 | $0.45 | +790.87% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $38 | $21.93 | +73.28% | 1 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $3 | $0.51 | +491.02% | 5 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $3.48 | +4,497.70% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $5 | $2.28 | +119.30% | 3 | Aug 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $44 | $2.75 | +1,500.00% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $90 | $1.87 | +4,712.83% | 4 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $4 | $0.59 | +580.97% | 1 | Jun 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $7 | $6.45 | +8.53% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $195 → $90 | $5.55 | +1,521.62% | 3 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $270 | $2.24 | +11,953.57% | 2 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $138 → $77 | $16.79 | +358.61% | 2 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,980 → $1,440 | $2.90 | +49,555.17% | 3 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $1.24 | +222.58% | 2 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $39 | $91.20 | -57.24% | 2 | Mar 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $11 | $1.83 | +501.09% | 1 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $34 | $3.47 | +879.83% | 1 | Mar 13, 2020 |
Nektar Therapeutics
Jan 8, 2025
Initiates: Buy
Price Target: $4
Current: $0.89
Upside: +348.43%
Cognition Therapeutics
Dec 19, 2024
Upgrades: Buy
Price Target: $1 → $1.5
Current: $0.68
Upside: +120.01%
Viking Therapeutics
Nov 22, 2024
Initiates: Buy
Price Target: $109
Current: $32.65
Upside: +233.84%
Madrigal Pharmaceuticals
Nov 5, 2024
Maintains: Neutral
Price Target: $194 → $236
Current: $293.64
Upside: -19.63%
Novavax
Oct 10, 2024
Reiterates: Buy
Price Target: $23 → $26
Current: $8.40
Upside: +209.52%
Trevi Therapeutics
Oct 7, 2024
Reiterates: Buy
Price Target: $6
Current: $3.76
Upside: +59.57%
Centessa Pharmaceuticals
Sep 19, 2024
Initiates: Buy
Price Target: $33
Current: $15.16
Upside: +117.68%
Harrow
Aug 29, 2024
Reiterates: Buy
Price Target: $50
Current: $33.85
Upside: +47.71%
Altimmune
Aug 12, 2024
Reiterates: Buy
Price Target: $20
Current: $6.86
Upside: +191.55%
Arrowhead Pharmaceuticals
Aug 12, 2024
Reiterates: Buy
Price Target: $55
Current: $19.56
Upside: +181.19%
Aug 7, 2024
Maintains: Buy
Price Target: $29 → $34
Current: $29.55
Upside: +15.06%
Jul 31, 2024
Downgrades: Neutral
Price Target: $18 → $5
Current: $3.00
Upside: +66.67%
Jun 4, 2024
Maintains: Buy
Price Target: $122 → $92
Current: $45.74
Upside: +101.14%
Jan 31, 2024
Upgrades: Buy
Price Target: $2
Current: $0.74
Upside: +170.27%
Dec 20, 2023
Maintains: Buy
Price Target: $8 → $4
Current: $3.18
Upside: +25.79%
Oct 13, 2023
Initiates: Buy
Price Target: $4
Current: $0.45
Upside: +790.87%
Sep 6, 2023
Initiates: Buy
Price Target: $38
Current: $21.93
Upside: +73.28%
Apr 10, 2023
Maintains: Buy
Price Target: $7 → $3
Current: $0.51
Upside: +491.02%
Mar 29, 2023
Reiterates: Buy
Price Target: $160
Current: $3.48
Upside: +4,497.70%
Aug 19, 2022
Downgrades: Neutral
Price Target: $11 → $5
Current: $2.28
Upside: +119.30%
Aug 11, 2022
Maintains: Buy
Price Target: $58 → $44
Current: $2.75
Upside: +1,500.00%
Jul 14, 2022
Maintains: Buy
Price Target: $120 → $90
Current: $1.87
Upside: +4,712.83%
Jun 14, 2022
Initiates: Buy
Price Target: $4
Current: $0.59
Upside: +580.97%
May 24, 2022
Downgrades: Neutral
Price Target: $14 → $7
Current: $6.45
Upside: +8.53%
Jan 24, 2022
Maintains: Buy
Price Target: $195 → $90
Current: $5.55
Upside: +1,521.62%
Nov 30, 2021
Maintains: Buy
Price Target: $500 → $270
Current: $2.24
Upside: +11,953.57%
Jan 15, 2021
Downgrades: Neutral
Price Target: $138 → $77
Current: $16.79
Upside: +358.61%
May 22, 2020
Downgrades: Neutral
Price Target: $1,980 → $1,440
Current: $2.90
Upside: +49,555.17%
Apr 3, 2020
Maintains: Buy
Price Target: $8 → $4
Current: $1.24
Upside: +222.58%
Mar 18, 2020
Maintains: Buy
Price Target: $47 → $39
Current: $91.20
Upside: -57.24%
Mar 13, 2020
Maintains: Buy
Price Target: $22 → $11
Current: $1.83
Upside: +501.09%
Mar 13, 2020
Maintains: Buy
Price Target: $43 → $34
Current: $3.47
Upside: +879.83%